14results about How to "Inhibit binding" patented technology

The application discloses a kind of antler active peptide and its application in anti-inflammatory, antioxidant and anti-aging, belong to the field of biotechnology.The application utilizes the first screening from antler new active peptide SPLASDLDL, realizes the competitive inhibition to TNFR1 by its specific binding with TNFR1 receptor characteristics.The polypeptide has anti-inflammatory, antioxidant and anti-aging effects by the constructed testicular Sertoli cell aging model.The application successfully solves the technical problems that prior art fails to find competitive inhibition TNFR1 targeting peptide from antler and elucidates its mechanism of action, provides the mechanism of action and scientific basis for developing new anti-inflammatory and anti-aging drugs from natural products.

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

This invention relates to the application of fatty acid-binding protein 4 (FABP4) inhibitors in the treatment of heart failure with preserved ejection fraction. Specifically, the application involves the oral administration of the fatty acid-binding protein 4 (FABP4) inhibitor BMS309403 for the prevention and / or treatment of heart failure with preserved ejection fraction.

This invention discloses the pharmaceutical applications of a P2Y11-specific inhibitor and compositions containing it, belonging to the field of biomedical technology. This invention discloses for the first time the use of NF157 in the preparation of drugs related to the treatment of HD5-induced pathogen infection. In combating pathogen infection, NF157 can specifically inhibit the binding of P2Y11 to HD5, thereby eliminating the role of HD5 in regulating cytoskeleton rearrangement and promoting filopodia formation, thus becoming a key link in interrupting pathogen infection. By preventing the formation of filopodia, NF157 effectively blocks the bacterial capture pathway, showing significant intervention effects on some pathogens that lack adhesion devices and flagella and rely on cellular pseudopodia capture for invasion.

This invention belongs to the field of medicine, specifically disclosing a drug-loaded biomimetic nanodecoy based on genetic engineering, its preparation method, and its application. The drug-loaded biomimetic nanodecoy of this invention comprises CCR2-overexpressing nanovesicles, and the hydrophobic regions of the nanovesicles are loaded with curcumin. This invention also provides a method for preparing the drug-loaded biomimetic nanodecoy based on genetic engineering and its application. The overexpressed CCR2 is used to adsorb excess CCL2 to inhibit the binding of macrophages to CCL2, preventing macrophage chemotaxis and subsequent TGF-β production. This inhibits the activation of hepatic stellate cells by removing pro-fibrotic mediators upstream; simultaneously, curcumin is released to block the downstream TGF-β / Smad signaling pathway, thereby inhibiting the activation of hepatic stellate cells.

The invention provides a preparation method of nano cobalt hydroxide, belongs to the technical field of preparation of lithium ion battery materials, and solves the problems that an existing nano cobalt hydroxide preparation process is complex, high in requirements for production equipment and unfavorable for large-scale product.The preparation method comprises the steps that a solution A and a solution B are prepared according to three conditions, and a synthetic reaction and aging are conducted after preparation; after aging is finished, washing the prepared cobalt hydroxide slurry; the washed cobalt hydroxide material is dried; and crushing the dried cobalt hydroxide to obtain a nanoscale cobalt hydroxide product. The prepared nanoscale cobalt hydroxide is small in specific surface area, does not need to add a dispersing agent, is simple in raw material and process, is easy to wash, and is easy for industrial production.

This invention provides the application of eugenin in the preparation of drugs for the treatment and / or prevention of inflammatory bowel disease. Using a DSS-induced C57BL / 6J mouse colitis model, this invention found that desulfovibrio flagellin (DVF) promotes intestinal inflammation, while eugenin treatment improves DVF-induced weight loss and inflammation-related parameters such as disease activity index in mice. Further investigation into the specific mechanism of its anti-inflammatory effect revealed that eugenin can act as an inhibitor of the interaction interface between DVF and NLR family apoptosis-inhibiting proteins (NAIP), thereby targeting and inhibiting the sustained activation of the NAIP / NLRC4 inflammasome and pyroptosis in macrophages, reducing the release of inflammatory factors. In conclusion, this traditional Chinese medicine monomer, eugenin, can provide a new approach for the future treatment of inflammatory bowel disease and related diseases.

The application discloses a phase change microcapsule composite heat storage material with photocatalytic characteristics and a preparation method thereof. The phase change microcapsule composite heat storage material has a whole core-shell structure, paraffin as a core, crystalline TiO2 with photocatalytic characteristics as a shell wall coated on the surface of the paraffin, and nano-titanium nitride and carbon nanotube composite blended photothermal conversion particles as core-shell modification materials uniformly attached to the surface of the TiO2. The phase change microcapsule composite heat storage material has a stable core-shell structure, full-spectrum solar photothermal conversion capacity, and effectively improves the coating rate, the thermal conductivity and the photocatalytic efficiency, retains the thermal properties of paraffin and inhibits leakage and corrosion.

The invention discloses a semiconductor structure and a corresponding chip and product. The structure comprises a silicon-based integrated circuit and a bump structure arranged on the silicon-based integrated circuit. The bump structure sequentially comprises a UBM layer, a copper conductor layer, a nickel conductor layer and a gold conductor layer. The exposed side walls of the UBM layer, the copper conductor layer and the nickel conductor layer are coated with a metal protection layer composed of palladium, palladium alloy, platinum or platinum alloy, and the protection layer does not cover the gold conductor layer. According to the preparation method, the step-shaped side wall is formed through etching steps in a specific sequence, selective self-growth of the protective layer on the titanium / copper / nickel side wall is achieved through chemical plating based on metal equilibrium potential difference, and the protective layer is not deposited on the gold surface. The problems of poor welding and short circuit caused by oxide generated by side wall oxidation and copper diffusion of the copper-nickel-gold bump are effectively solved, the long-term reliability is remarkably improved, meanwhile, the using amount of precious metal is small, the technology is ingenious, and the method is particularly suitable for the high-end display field of liquid crystal driving chips and the like.

This invention discloses a method for preparing electrode slurry for high-rate lithium batteries and its coating process, belonging to the field of lithium battery technology. Using chitosan as a carbon source, modified titanium carbide nanosheets are composited with nickel-cobalt-doped silicon spheres via glutaraldehyde crosslinking. High-temperature carbonization forms a carbon coating. The carbon-coated composite porous microspheres are then mixed with nano-copper powder, conductive carbon black, and sodium carboxymethyl cellulose solution, and subjected to gradient stirring to obtain the electrode slurry for high-rate lithium batteries. This invention utilizes the synergistic effect of metal-doped porous silicon spheres and modified titanium carbide nanosheets with carbon coating to construct a conductive network, allowing metal ions to be uniformly anchored on the surface and within the pores of the silicon spheres. This improves the conductivity of the silicon-based material and alleviates particle pulverization caused by silicon volume expansion. The carbon coating forms a "core-shell" structure, achieving high conductivity and high rate capability in the electrode slurry.

This invention belongs to the field of biomedical technology and relates to a polypeptide targeting cGAS and its applications. The polypeptide comprises an active peptide and a membrane-penetrating peptide, the membrane-penetrating peptide being fused to the N-terminus of the active peptide. The amino acid sequence of the active peptide is identical to amino acid regions 45-63 of human IκB kinase-binding protein (IKIP) or 43-60 of mouse IKIP. The polypeptide provided by this invention can enter cells, specifically bind to cGAS, inhibit cGAS aggregation and phase separation, thereby inhibiting cGAS enzyme activity, reducing type I interferon expression, maintaining antiviral immune homeostasis, and providing a new candidate strategy for the clinical treatment of viral infections and autoimmune diseases.

This invention belongs to the field of molecular biology and drug screening technology, and provides a method for screening capsaicin targeting SOCS5-RBMX protein interactions and its application. The method involves analyzing the structure of the SOCS5-RBMX protein complex to determine the SOCS5-RBMX binding domain and key binding sites; verifying the inhibitory effect on protein binding through point mutations at these key sites; identifying the binding pocket; using drugs from the ZINC22 small molecule drug database and FDA-approved drugs as ligand molecules, and performing virtual screening with the binding pocket as the docking region to obtain compounds; screening the obtained compounds using AMDET to identify capsaicin as the drug inhibiting SOCS5-RBMX binding; and further screening and verification using capsaicin in in vivo and in vitro experiments. This invention, through the analysis of the SOCS5-RBMX protein complex structure to determine the binding domain and key sites, and then using this as a basis for virtual screening and experimental verification, can accurately screen for drugs inhibiting SOCS5-RBMX binding, improving the accuracy and efficiency of drug screening.

The application relates to the technical field of biology, and discloses a nanobody targeting a receptor binding domain of a novel coronavirus SARS-CoV-2 as well as a preparation method and application thereof. The application also discloses biological materials, derivative antibodies and detection reagents related to the nanobody. The nanobody disclosed by the application mainly recognizes a receptor binding motif region combined with RBD. The nanobody comprises complementarity determining regions CDR1, CDR2 and CDR3, and can also comprise a framework region FR. The nanobody disclosed by the application can be combined with SARS-CoV-2 in a high-efficiency and specific manner, and the affinity can reach a picomolar level. Meanwhile, the nanobody provided by the application has good neutralization biological activity, and the recognition and combination mechanism is clear, so that excellent effects can be obtained in SARS-CoV-2 detection or diseases caused by SARS-CoV-2. The application can be applied to the fields of biology and medicine.

The invention belongs to the technical field of medicines, and discloses an N-phenyl-6-oxo-1, 6-dihydropyridine-3-formamide compound as well as a preparation method and an application of the N-phenyl-6-oxo-1, 6-dihydropyridine-3-formamide compound. The N-phenyl-6-oxo-1, 6-dihydropyridine-3-formamide compound prepared by the preparation method disclosed by the invention can play a dual role in inhibiting the activity of JNK2 kinase and interfering the combination of JNK2 and upstream protein MKK7. Experiments show that the N-phenyl-6-oxo-1, 6-dihydropyridine-3-formamide compound can inhibit the activity of JNK2 kinase, the inhibitory activity IC50 of the preferable compound 1l to the JNK2 is 0.99 M, and the N-phenyl-6-oxo-1, 6-dihydropyridine-3-formamide compound can inhibit the combination of the JNK2 and upstream protein MKK7. In addition, the compound 1l also shows a good treatment effect on mouse type 2 diabetic nephropathy (T2DM) induced by high fat diet and streptozotocin.